Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis.

BACKGROUND

Previous meta-analysis had concluded that desferrioxamine mesylate (DFO) could effectively treat intracerebral hematoma (ICH) in animal models. We hope to confirm that DFO could treat ICH patients effectively through the systemic review and meta-analysis of clinical researches.

METHOD

Data extraction included hematoma volume (HV), reduction of National Institute of Health Stroke Scale (NIHSS) scores, and relative perihematomal edema (RPHE). The standard mean difference (SMD) and 95% confidence interval (95%CI) were calculated by fixed effects model. I-square (I) statistic was used to test the heterogeneity. All p values were two-side with a significant level at 0.05.

RESULTS

Five randomized controlled trials were included in the meta-analysis, which included 239 patients. At 7 days after onset, there was significant difference of RPHE development (- 1.87 (- 2.22, - 1.51) (I = 0, p = 0.639)) and significant difference of HV absorption (- 0.71 (- 1.06, 0.36) (I = 17.5%, p = 0.271)) between DFO and control groups. There was significant difference of reduction of NHISS scores (0.25 (0.05, 0.46) (I = 0, p = 0.992)) between DFO and control groups at 30 days after onset.

CONCLUSION

DFO reduced HV and perihematomal edema in ICH patients at 7 days after onset and improve neurological function at 30 days after onset efficiently and safely. DFO might be a new route of improving treatment of ICH.